摘要
胰腺导管腺癌(PDA)仍然是全球范围内一个毁灭性的疾病。虽然其病理生理学研究方面已取得显著进展,但PDA患者仅少数蛋白可能从治疗性手术和当前化疗中受益。因此,目前迫切需要开发新的有效治疗方法用于PDA的治疗。目前,大蒜产品已作为治疗癌症的一个有效的重要药物来源。最近,我们鉴定了大蒜新的活性成分,S-炔丙基-L-半胱氨酸(SPRC)、S-烯丙基半胱氨酸(SAC)的类似物。虽然已经显示出对几种癌症的抗癌活性,但其作用机制尚不完全清楚。本研究旨在首次确定PDA中SPRC的抗癌活性及其体外和体内的潜在作用机制。我们的研究结果表明,SPRC降低细胞活力和集落形成,抑制细胞增殖,诱导G2/M期具有不同p53状态的PDA细胞周期阻滞和凋亡。此外,SPRC在Panc-1异种移植模型中抑制肿瘤生长。我们还表明,SPRC通过增加其磷酸化,并降低其泛素化介导的降解JNK蛋白水平的调控作用实现其抗癌作用。总之,SPRC具有显著的抗PDA活性和效果且不依赖于p53,可能是通过激活JNK信号传导通路起作用,作为一种新的PDA靶向抗癌治疗剂,为开发该化合物提供基础。
关键词: 凋亡,化疗,大蒜衍生物,JNK,胰腺癌,S-炔丙基-L-半胱氨酸
Current Cancer Drug Targets
Title:The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo
Volume: 15 Issue: 7
Author(s): Wei Wang, Jianwen Cheng and Yizhun Zhu
Affiliation:
关键词: 凋亡,化疗,大蒜衍生物,JNK,胰腺癌,S-炔丙基-L-半胱氨酸
摘要: Pancreatic ductal adenocarcinoma (PDA) remains a devastating disease worldwide. Although significant improvement has been made in understanding its pathophysiology, only small portion of patients with PDA are likely to benefit from curative surgery and current chemotherapy. Thus, there is an urgent need for developing novel effective therapeutic approaches to the treatment of PDA. Today, garlic products have become an important source of effective compounds for the treatment of cancer. We have recently identified a novel garlic active component, S-propargyl-L-cysteine (SPRC), an analogue of S-Allyl Cysteine (SAC). Although its anticancer activity has been shown against several cancers, the mechanism of action is not fully understood. The present study was first designed to determine the anticancer activity of SPRC in PDA and the underlying mechanisms of action in vitro and in vivo. Our results demonstrated that SPRC reduced cell viability and colony formation, inhibited cell proliferation, induced G2/M phase cell cycle arrest and apoptosis in human PDA cells with various p53 statuses (HPAC, p53 wt; Panc-1, p53 mt). Furthermore, SPRC inhibited tumor growth in Panc-1 xenograft models. We also demonstrated that SPRC achieved its anticancer effects by regulation of the JNK protein levels through increasing its phosphorylation and decreasing its polyubiquitination-mediated degradation. In conclusion, SPRC has significant anti-PDA activity and the effects do not depend on p53 status, presumably through activating the JNK signaling pathway, providing a basis for the development of this compound as a novel target anticancer therapeutic agent for PDA.
Export Options
About this article
Cite this article as:
Wei Wang, Jianwen Cheng and Yizhun Zhu , The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150602143943
DOI https://dx.doi.org/10.2174/1568009615666150602143943 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Insights and Perspectives of Nitric Oxide-mediated Biofilm Eradication
Current Topics in Medicinal Chemistry Medherb: An Interactive Bioinformatics Database and Analysis Resource for Medicinally Important Herbs
Current Bioinformatics TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Recent Patents Review in Microencapsulation of Pharmaceuticals Using the Emulsion Solvent Removal Methods
Recent Patents on Drug Delivery & Formulation MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Profilin1 Sensitizes Pancreatic Cancer Cells to Irradiation by Inducing Apoptosis and Reducing Autophagy
Current Molecular Medicine Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences Synthesis and Characterization of Novel pH-sensitive Nano Composites for Oral Drug Delivery
Current Nanoscience Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry Therapy Related Markers and Response Prediction Towards Multimodal Treatment of Carcinomas of the Upper Gastrointestinal Tract
Current Pharmacogenomics and Personalized Medicine Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents